Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
The DUPLEX FSGS Study
Study of Sparsentan in FSGS (DUPLEX)
Brief Description
*Enrollment is now closed. We will keep you updated on the results of this study as they are published. This clinical trial will determine the effectiveness of Sparsentan at reducing proteinuria in patients with primary FSGS.
Trial Physician / Study Coordinator
Jung Hee Kim
EmailSite Name
Seoul National University Hospital
101 Daehak-ro, Ihwa-dong, Jongno-gu, Seoul, South Korea
Sponsor
Travere Therapeutics
Study Drug
Sparsentan
Estimated enrollment
300
Estimated end date
December, 2022
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
The DUPLEX FSGS Study
Study of Sparsentan in FSGS (DUPLEX)
Brief Description
*Enrollment is now closed. We will keep you updated on the results of this study as they are published. This clinical trial will determine the effectiveness of Sparsentan at reducing proteinuria in patients with primary FSGS.
Trial is for people with
Primary focal segmental glomerulosclerosis (FSGS)
Study Goal
To determine if sparsentan is works better than irbesartan at reducing proteinuria and reducing the rate of kidney damage caused by FSGS.
What is involved for the Patient?
Eligible participants will need to visit the study location 17 times. There will also be times they need to speak by telephone to study team personnel at the study location. The study will last 2 years and 3 months.
About the drug or intervention
Sparsentan is a dual-acting angiotensin receptor blocker and endothelin receptor antagonist.